Concizumab
- CAS No.
- 1312299-39-0
- Chemical Name:
- Concizumab
- Synonyms
- Concizumab;mAb 2021|||NN 7415;Concizumab (anti-TFPI);Research Grade Concizumab;Research Grade Concizumab (DHC82802)
- CBNumber:
- CB28080871
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 68603V9EAF |
Concizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620996 | Concizumab 95.00% | 1312299-39-0 | 1mg | $379 | 2026-06-04 | Buy |
| ChemScene | CS-0620996 | Concizumab 95.00% | 1312299-39-0 | 5mg | $986 | 2026-06-04 | Buy |
| ChemScene | CS-0620996 | Concizumab 95.00% | 1312299-39-0 | 10mg | $1582 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1290225 | Concizumab >95% | 100μg | $280 | 2026-05-06 | Buy | |
| Biorbyt Ltd | orb1290225 | Concizumab >95% | 1mg | $820 | 2026-05-06 | Buy |
Concizumab Chemical Properties, Uses, Production
Uses
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia[1][2].
in vivo
Concizumab (i.v./s.c.) blocks the TFPI interaction with the active site of FXa in cynomolgus monkeys[2].
| Parameter | Unit | Estimate | %RSE |
| CLL | mL/h/kg | 0.14 | 6.1 |
| V1 | mL/kg | 33 | 34 |
| V2 | mL/kg | 33 | - |
| Q | mL/h/kg | 0.12 | 16 |
| F | % | 93 | 7.7 |
| Vmax | μg/h/kg | 11 | 17 |
| Km | μg/mL | 0.54 | 52 |
| t1/2(abs) | h | 72 | 32 |
CLL: the linear part of the clearance.
V1: the volume of the central compartment.
V2: the volume of the peripheral compartment.
Vmax: the maximum amount of anti-TFPI cleared per time unit via binding to TFPI.
Km: the concentration at which the target mediated elimination rate is 50% of the maximum value (Vmax).
T1/2(abs): the absorption half-life, describing the rate of absorption after sc administration.
%RSE: residual standard error.
| Animal Model: | Cynomolgus monkeys (target mediated drug disposition (TMDD) model)[2]. |
| Dosage: | 20mg/kg or 200 mg/kg |
| Administration: | Intravenous injection/subcutaneous injection |
| Result: | Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h. |
References
[1] Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. DOI:10.1111/jth.15323
[2] Agers H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9. DOI:10.1016/j.ejps.2014.02.009
Concizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Concizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
